Skip to main content
Top
Published in: Breast Cancer Research 5/2011

Open Access 01-10-2011 | Research article

Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study

Authors: Harri Sihto, Johan Lundin, Mikael Lundin, Tiina Lehtimäki, Ari Ristimäki, Kaija Holli, Liisa Sailas, Vesa Kataja, Taina Turpeenniemi-Hujanen, Jorma Isola, Päivi Heikkilä, Heikki Joensuu

Published in: Breast Cancer Research | Issue 5/2011

Login to get access

Abstract

Introduction

Some molecular subtypes of breast cancer have preferential sites of distant relapse. The protein expression pattern of the primary tumor may influence the first distant metastasis site.

Methods

We identified from the files of the Finnish Cancer Registry patients diagnosed with breast cancer in five geographical regions Finland in 1991-1992, reviewed the hospital case records, and collected primary tumor tissue. Out of the 2,032 cases identified, 234 developed distant metastases after a median follow-up time of 2.7 years and had the first metastatic site documented (a total of 321 sites). Primary tumor microarray (TMA) cores were analyzed for 17 proteins using immunohistochemistry and for erbB2 using chromogenic in situ hybridization, and their associations with the first metastasis site were examined. The cancers were classified into luminal A, luminal B, HER2+ enriched, basal-like or non-expressor subtypes.

Results

A total of 3,886 TMA cores were analyzed. Luminal A cancers had a propensity to give rise first to bone metastases, HER2-enriched cancers to liver and lung metastases, and basal type cancers to liver and brain metastases. Primary tumors that gave first rise to bone metastases expressed frequently estrogen receptor (ER) and SNAI1 (SNAIL) and rarely COX2 and HER2, tumors with first metastases in the liver expressed infrequently SNAI1, those with lung metastases expressed frequently the epidermal growth factor receptor (EGFR), cytokeratin-5 (CK5) and HER2, and infrequently progesterone receptor (PgR), tumors with early skin metastases expressed infrequently E-cadherin, and breast tumors with first metastases in the brain expressed nestin, prominin-1 and CK5 and infrequently ER and PgR.

Conclusions

Breast tumor biological subtypes have a tendency to give rise to first distant metastases at certain body sites. Several primary tumor proteins were associated with homing of breast cancer cells.
Appendix
Available only for authorised users
Literature
1.
go back to reference Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2002, 55: 74-108.CrossRef Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2002, 55: 74-108.CrossRef
2.
go back to reference Schopper D, de Wolf C: How effective are breast cancer screening programmes by mammography? Review of the current evidence. Eur J Cancer. 2009, 45: 1916-1923. 10.1016/j.ejca.2009.03.022.CrossRefPubMed Schopper D, de Wolf C: How effective are breast cancer screening programmes by mammography? Review of the current evidence. Eur J Cancer. 2009, 45: 1916-1923. 10.1016/j.ejca.2009.03.022.CrossRefPubMed
3.
go back to reference Anderson WF, Reeves JE, Abdalla E, Berkel HJ: Outcome of patients with metastatic breast carcinoma treated a private medical oncology clinic. Cancer. 2000, 88: 95-107. 10.1002/(SICI)1097-0142(20000101)88:1<95::AID-CNCR14>3.0.CO;2-P.CrossRefPubMed Anderson WF, Reeves JE, Abdalla E, Berkel HJ: Outcome of patients with metastatic breast carcinoma treated a private medical oncology clinic. Cancer. 2000, 88: 95-107. 10.1002/(SICI)1097-0142(20000101)88:1<95::AID-CNCR14>3.0.CO;2-P.CrossRefPubMed
4.
go back to reference Largillier R, Ferrero JM, Doyen J, Barriere J, Namer M, Mari V, Courdi A, Hannoun-Levi JM, Ettore F, Birtwisle-Peyrottes I, Balu-Maestro C, Marcy PY, Raoust I, Lallement M, Chamorey E: Prognostic factors in 1038 women with metastatic breast cancer. Annals of Oncology. 2008, 19: 2012-2019. 10.1093/annonc/mdn424.CrossRefPubMedPubMedCentral Largillier R, Ferrero JM, Doyen J, Barriere J, Namer M, Mari V, Courdi A, Hannoun-Levi JM, Ettore F, Birtwisle-Peyrottes I, Balu-Maestro C, Marcy PY, Raoust I, Lallement M, Chamorey E: Prognostic factors in 1038 women with metastatic breast cancer. Annals of Oncology. 2008, 19: 2012-2019. 10.1093/annonc/mdn424.CrossRefPubMedPubMedCentral
5.
go back to reference van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002, 347: 1999-2009. 10.1056/NEJMoa021967.CrossRefPubMed van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002, 347: 1999-2009. 10.1056/NEJMoa021967.CrossRefPubMed
6.
go back to reference Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005, 365: 671-679.CrossRefPubMed Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005, 365: 671-679.CrossRefPubMed
7.
go back to reference Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lønning P, Børresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci. 2001, 98: 10869-10874. 10.1073/pnas.191367098.CrossRefPubMedPubMedCentral Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lønning P, Børresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci. 2001, 98: 10869-10874. 10.1073/pnas.191367098.CrossRefPubMedPubMedCentral
8.
go back to reference Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, Foekens JA, Martens JW: Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008, 68: 3108-3114. 10.1158/0008-5472.CAN-07-5644.CrossRefPubMed Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, Foekens JA, Martens JW: Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008, 68: 3108-3114. 10.1158/0008-5472.CAN-07-5644.CrossRefPubMed
9.
go back to reference Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005, 11: 5678-5685. 10.1158/1078-0432.CCR-04-2421.CrossRefPubMed Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005, 11: 5678-5685. 10.1158/1078-0432.CCR-04-2421.CrossRefPubMed
10.
go back to reference Hugh J, Hanson J, Cheang MC, Nielsen TO, Perou CM, Dumontet C, Reed J, Krajewska M, Treilleux I, Rupin M, Magherini E, Mackey J, Martin M, Vogel C: Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol. 2009, 27: 1168-1176. 10.1200/JCO.2008.18.1024.CrossRefPubMedPubMedCentral Hugh J, Hanson J, Cheang MC, Nielsen TO, Perou CM, Dumontet C, Reed J, Krajewska M, Treilleux I, Rupin M, Magherini E, Mackey J, Martin M, Vogel C: Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol. 2009, 27: 1168-1176. 10.1200/JCO.2008.18.1024.CrossRefPubMedPubMedCentral
11.
go back to reference Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006, 295: 2492-2502. 10.1001/jama.295.21.2492.CrossRefPubMed Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006, 295: 2492-2502. 10.1001/jama.295.21.2492.CrossRefPubMed
12.
go back to reference Kennecke H, Yerushalmi R, Woods R, Cheang MCU, Voduc D, Speers CH, Nielsen TO, Gelmon K: Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010, 20: 3271-3277.CrossRef Kennecke H, Yerushalmi R, Woods R, Cheang MCU, Voduc D, Speers CH, Nielsen TO, Gelmon K: Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010, 20: 3271-3277.CrossRef
13.
go back to reference Hess KR, Pusztai L, Buzdar AU, Hortogabyi GN: Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat. 2003, 78: 105-118. 10.1023/A:1022166517963.CrossRefPubMed Hess KR, Pusztai L, Buzdar AU, Hortogabyi GN: Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat. 2003, 78: 105-118. 10.1023/A:1022166517963.CrossRefPubMed
14.
go back to reference Niwinska A, Murawska M, Pogoda K: Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol. 2010, 21: 942-948. 10.1093/annonc/mdp407.CrossRefPubMed Niwinska A, Murawska M, Pogoda K: Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol. 2010, 21: 942-948. 10.1093/annonc/mdp407.CrossRefPubMed
15.
go back to reference Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R: Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer. 2006, 107: 696-704. 10.1002/cncr.22041.CrossRefPubMed Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R: Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer. 2006, 107: 696-704. 10.1002/cncr.22041.CrossRefPubMed
16.
go back to reference Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, Crivellari D, Fey MF, Murray E, Pagani O, Simoncini E, Castiglione-Gertsch M, Gelber RD, Coates AS, Goldhirsch A: Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol. 2006, 17: 935-944. 10.1093/annonc/mdl064.CrossRefPubMed Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, Crivellari D, Fey MF, Murray E, Pagani O, Simoncini E, Castiglione-Gertsch M, Gelber RD, Coates AS, Goldhirsch A: Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol. 2006, 17: 935-944. 10.1093/annonc/mdl064.CrossRefPubMed
17.
go back to reference Lundin J, Lundin M, Holli K, Kataja V, Elomaa L, Pylkkänen L, Turpeenniemi-Hujanen T, Joensuu H: Omission of histologic grading from clinical decision making may result in overuse of adjuvant therapies in breast cancer: results from a nationwide study. J Clin Oncol. 2001, 19: 28-36.PubMed Lundin J, Lundin M, Holli K, Kataja V, Elomaa L, Pylkkänen L, Turpeenniemi-Hujanen T, Joensuu H: Omission of histologic grading from clinical decision making may result in overuse of adjuvant therapies in breast cancer: results from a nationwide study. J Clin Oncol. 2001, 19: 28-36.PubMed
18.
go back to reference Joensuu H, Isola J, Lundin M, Salminen T, Holli K, Kataja V, Pylkkänen L, Turpeenniemi-Hujanen T, von Smitten K, Lundin J: Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res. 2003, 9: 923-930.PubMed Joensuu H, Isola J, Lundin M, Salminen T, Holli K, Kataja V, Pylkkänen L, Turpeenniemi-Hujanen T, von Smitten K, Lundin J: Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res. 2003, 9: 923-930.PubMed
19.
go back to reference Subhawong AP, Subhawong T, Nassar H, Kouprina N, Begum S, Vang R, Westra WH, Argani P: Most basal-like carcinomas demonstrate the same Rb-/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically. Am J Surg Path. 2009, 33: 163-175. 10.1097/PAS.0b013e31817f9790.CrossRefPubMedPubMedCentral Subhawong AP, Subhawong T, Nassar H, Kouprina N, Begum S, Vang R, Westra WH, Argani P: Most basal-like carcinomas demonstrate the same Rb-/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically. Am J Surg Path. 2009, 33: 163-175. 10.1097/PAS.0b013e31817f9790.CrossRefPubMedPubMedCentral
20.
go back to reference Sihto H, Lundin J, Lehtimäki T, Sarlomo-Rikala M, Bützow R, Holli K, Sailas L, Kataja V, Lundin M, Turpeenniemi-Hujanen T, Isola J, Heikkilä P, Joensuu H: Molecular subtypes of breast cancers detected in mammography screening and outside of screening. Clin Cancer Res. 2008, 14: 4103-4110. 10.1158/1078-0432.CCR-07-5003.CrossRefPubMed Sihto H, Lundin J, Lehtimäki T, Sarlomo-Rikala M, Bützow R, Holli K, Sailas L, Kataja V, Lundin M, Turpeenniemi-Hujanen T, Isola J, Heikkilä P, Joensuu H: Molecular subtypes of breast cancers detected in mammography screening and outside of screening. Clin Cancer Res. 2008, 14: 4103-4110. 10.1158/1078-0432.CCR-07-5003.CrossRefPubMed
21.
go back to reference Sihto H, Tynninen O, Bützow R, Saarialho-Kere U, Joensuu H: Endothelial cell KIT expression in human tumours. J Pathol. 2007, 211: 481-488. 10.1002/path.2125.CrossRefPubMed Sihto H, Tynninen O, Bützow R, Saarialho-Kere U, Joensuu H: Endothelial cell KIT expression in human tumours. J Pathol. 2007, 211: 481-488. 10.1002/path.2125.CrossRefPubMed
22.
go back to reference Ristimäki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J: Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002, 62: 632-635.PubMed Ristimäki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J: Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002, 62: 632-635.PubMed
23.
go back to reference Stuart-Harris R, Caldas C, Pinder SE, Pharoah P: Proliferation markers and survival in early breast cancer: A systematic review and meta-analysis of 85 studies in 32,825 patients. Breast. 2008, 17: 323-334. 10.1016/j.breast.2008.02.002.CrossRefPubMed Stuart-Harris R, Caldas C, Pinder SE, Pharoah P: Proliferation markers and survival in early breast cancer: A systematic review and meta-analysis of 85 studies in 32,825 patients. Breast. 2008, 17: 323-334. 10.1016/j.breast.2008.02.002.CrossRefPubMed
24.
go back to reference Solomayer EF, Diel IJ, Meyberg GC, Gollan C, Bastert G: Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat. 2000, 59: 271-278. 10.1023/A:1006308619659.CrossRefPubMed Solomayer EF, Diel IJ, Meyberg GC, Gollan C, Bastert G: Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat. 2000, 59: 271-278. 10.1023/A:1006308619659.CrossRefPubMed
25.
go back to reference Schmalhofer O, Brabletz S, Brabletz T: E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 2009, 1-2: 151-166.CrossRef Schmalhofer O, Brabletz S, Brabletz T: E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 2009, 1-2: 151-166.CrossRef
26.
go back to reference Valsecchi ME, Pomerantz SC, Jaslow R, Tester W: Reduced risk of bone metastasis for patients with breast cancer who use COX-2 inhibitors. Clin Breast Cancer. 2009, 4: 225-230.CrossRef Valsecchi ME, Pomerantz SC, Jaslow R, Tester W: Reduced risk of bone metastasis for patients with breast cancer who use COX-2 inhibitors. Clin Breast Cancer. 2009, 4: 225-230.CrossRef
27.
go back to reference Kedrin D, Wyckoff J, Boimel PJ, Coniglio SJ, Hynes NE, Arteaga CL, Segall JE: ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation. Clin Cancer Res. 2009, 15: 3733-3739. 10.1158/1078-0432.CCR-08-2163.CrossRefPubMedPubMedCentral Kedrin D, Wyckoff J, Boimel PJ, Coniglio SJ, Hynes NE, Arteaga CL, Segall JE: ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation. Clin Cancer Res. 2009, 15: 3733-3739. 10.1158/1078-0432.CCR-08-2163.CrossRefPubMedPubMedCentral
28.
go back to reference Gupta GP, Nguyen DX, Chiang AC, Bos PD, Kim JY, Nadal C, Gomis RR, Manova-Todorova K, Massagué J: Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature. 2007, 446: 6740-6745.CrossRef Gupta GP, Nguyen DX, Chiang AC, Bos PD, Kim JY, Nadal C, Gomis RR, Manova-Todorova K, Massagué J: Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature. 2007, 446: 6740-6745.CrossRef
29.
go back to reference Choi YJ, Nam SJ, Son MJ, Kim DK, Kim JH, Young JH, Kim MH, Song HS, Nam DH, Bang SI: Erlotinib prevents pulmonary metastasis in curatively resected breast carcinoma using a mouse model. Oncol Rep. 2006, 16: 119-122.PubMed Choi YJ, Nam SJ, Son MJ, Kim DK, Kim JH, Young JH, Kim MH, Song HS, Nam DH, Bang SI: Erlotinib prevents pulmonary metastasis in curatively resected breast carcinoma using a mouse model. Oncol Rep. 2006, 16: 119-122.PubMed
30.
go back to reference Da Silva L, Simpson PT, Smart CE, Cocciardi S, Waddell N, Lane A, Morrison BJ, Vargas AC, Healey S, Beesley J, Pakkiri P, Parry S, Kurniawan N, Reid L, Keith P, Faria P, Pereira E, Skalova A, Bilous M, Balleine RL, Do H, Dobrovic A, Fox S, Franco M, Reynolds B, Khanna KK, Cummings M, Chenevix-Trench G, Lakhani SR: HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. Breast Cancer Research. 2010, 12: R46-10.1186/bcr2603.CrossRefPubMedPubMedCentral Da Silva L, Simpson PT, Smart CE, Cocciardi S, Waddell N, Lane A, Morrison BJ, Vargas AC, Healey S, Beesley J, Pakkiri P, Parry S, Kurniawan N, Reid L, Keith P, Faria P, Pereira E, Skalova A, Bilous M, Balleine RL, Do H, Dobrovic A, Fox S, Franco M, Reynolds B, Khanna KK, Cummings M, Chenevix-Trench G, Lakhani SR: HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. Breast Cancer Research. 2010, 12: R46-10.1186/bcr2603.CrossRefPubMedPubMedCentral
31.
go back to reference Leyland-Jones B: Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol. 2009, 27: 5278-5286. 10.1200/JCO.2008.19.8481.CrossRefPubMed Leyland-Jones B: Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol. 2009, 27: 5278-5286. 10.1200/JCO.2008.19.8481.CrossRefPubMed
32.
go back to reference Musolino A, Ciccolallo L, Panebianco M, Fontana E, Zanoni D, Bozzetti C, Michiara M, Silini EM, Ardizzoni A: Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study. Cancer. 2011, 117: 1837-1846. 10.1002/cncr.25771.CrossRefPubMed Musolino A, Ciccolallo L, Panebianco M, Fontana E, Zanoni D, Bozzetti C, Michiara M, Silini EM, Ardizzoni A: Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study. Cancer. 2011, 117: 1837-1846. 10.1002/cncr.25771.CrossRefPubMed
33.
go back to reference Tsukada Y, Fouad A, Pickren JW, Lane WW: Central nervous system metastasis from breast carcinoma: autopsy study. Cancer. 1983, 52: 2349-2354. 10.1002/1097-0142(19831215)52:12<2349::AID-CNCR2820521231>3.0.CO;2-B.CrossRefPubMed Tsukada Y, Fouad A, Pickren JW, Lane WW: Central nervous system metastasis from breast carcinoma: autopsy study. Cancer. 1983, 52: 2349-2354. 10.1002/1097-0142(19831215)52:12<2349::AID-CNCR2820521231>3.0.CO;2-B.CrossRefPubMed
34.
go back to reference Wu JM, Fackler JM, Haluska DW, Molavi DW, Taylor ME, Teo WW, Griffin C, Fetting J, Davidson NE, De Marzo AM, Hicks JL, Chitale D, Ladanyi M, Sukumar S, Argani P: Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res. 2008, 14: 1938-1946. 10.1158/1078-0432.CCR-07-4082.CrossRefPubMedPubMedCentral Wu JM, Fackler JM, Haluska DW, Molavi DW, Taylor ME, Teo WW, Griffin C, Fetting J, Davidson NE, De Marzo AM, Hicks JL, Chitale D, Ladanyi M, Sukumar S, Argani P: Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res. 2008, 14: 1938-1946. 10.1158/1078-0432.CCR-07-4082.CrossRefPubMedPubMedCentral
35.
go back to reference Dell'Albani P: Stem cell markers in gliomas. Neurochem Res. 2008, 33: 2407-2415. 10.1007/s11064-008-9723-8.CrossRefPubMed Dell'Albani P: Stem cell markers in gliomas. Neurochem Res. 2008, 33: 2407-2415. 10.1007/s11064-008-9723-8.CrossRefPubMed
36.
go back to reference Florek M, Haase M, Marzesco AM, Freund D, Ehninger G, Huttner WB, Corbeil D: Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell Tissue Res. 2005, 319: 15-26. 10.1007/s00441-004-1018-z.CrossRefPubMed Florek M, Haase M, Marzesco AM, Freund D, Ehninger G, Huttner WB, Corbeil D: Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell Tissue Res. 2005, 319: 15-26. 10.1007/s00441-004-1018-z.CrossRefPubMed
37.
go back to reference Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB: Identification of human brain tumour initiating cells. Nature. 2004, 432: 396-401. 10.1038/nature03128.CrossRefPubMed Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB: Identification of human brain tumour initiating cells. Nature. 2004, 432: 396-401. 10.1038/nature03128.CrossRefPubMed
38.
go back to reference Aitken SJ, Thomas JS, Langdon SP, Harrison DJ, Faratian D: Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann Oncol. 2010, 21: 1254-1261. 10.1093/annonc/mdp427.CrossRefPubMed Aitken SJ, Thomas JS, Langdon SP, Harrison DJ, Faratian D: Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann Oncol. 2010, 21: 1254-1261. 10.1093/annonc/mdp427.CrossRefPubMed
39.
go back to reference Simmons C, Miller N, Geddie W, Gianfelice D, Oldfield M, Dranitsaris G, Clemons MJ: Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?. Ann Oncol. 2009, 20: 1499-1504. 10.1093/annonc/mdp028.CrossRefPubMedPubMedCentral Simmons C, Miller N, Geddie W, Gianfelice D, Oldfield M, Dranitsaris G, Clemons MJ: Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?. Ann Oncol. 2009, 20: 1499-1504. 10.1093/annonc/mdp028.CrossRefPubMedPubMedCentral
40.
go back to reference Wu JM, Halushka MK, Argani P: Intratumoral heterogeneity of HER-2 gene amplification and protein overexpression in breast cancer. Hum Pathol. 2010, 41: 914-917. 10.1016/j.humpath.2009.10.022.CrossRefPubMedPubMedCentral Wu JM, Halushka MK, Argani P: Intratumoral heterogeneity of HER-2 gene amplification and protein overexpression in breast cancer. Hum Pathol. 2010, 41: 914-917. 10.1016/j.humpath.2009.10.022.CrossRefPubMedPubMedCentral
41.
go back to reference Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC: American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010, 28: 2784-2795. 10.1200/JCO.2009.25.6529.CrossRefPubMedPubMedCentral Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC: American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010, 28: 2784-2795. 10.1200/JCO.2009.25.6529.CrossRefPubMedPubMedCentral
Metadata
Title
Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study
Authors
Harri Sihto
Johan Lundin
Mikael Lundin
Tiina Lehtimäki
Ari Ristimäki
Kaija Holli
Liisa Sailas
Vesa Kataja
Taina Turpeenniemi-Hujanen
Jorma Isola
Päivi Heikkilä
Heikki Joensuu
Publication date
01-10-2011
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 5/2011
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2944

Other articles of this Issue 5/2011

Breast Cancer Research 5/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine